Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture

Cancer Immunology, Immunotherapy

Volumn 56, Issue 3, 2007, Pages 359-370

  Berencsi, Klara ^a   Meropol, Neal J ^b   Hoffman, John P ^b   Sigurdson, Elin ^b   Giles, Lydia ^b   Rani, Pyapalli ^a   Somasundaram, Rajasekharan ^a   Zhang, Tianqian ^a   Kalabis, Jiri ^a   Caputo, Laura ^a   Furth, Emma ^c   Swoboda, Rolf ^a   Marincola, Francesco ^d   Herlyn, Dorothee ^a  

^a WISTAR INSTITUTE   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Apoptosis; Chemokines; Chemotaxis; CTL; Tumor immunity

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CYTOKINE ANTIBODY; RECEPTOR ANTIBODY;

ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL MIGRATION; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE MIGRATION INHIBITION; LYMPHOCYTE MIGRATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR IMMUNITY;

APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINES, CXC; COLONIC NEOPLASMS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; PHENOTYPE; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC; TISSUE CULTURE TECHNIQUES;

EID: 33845994752     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0190-2     Document Type: Article

References (53)

1. Aiba S, Nakagawa S, Hara M, Tomioka Y, Deguchi M, Tagami H (1994) Cultured murine dermal cells can function like thymic nurse cells. J Invest Dermatol 103:162-167
2. Belperio JA, Keane MP, Burdick MD, Lynch III JP, Xue YY, Li K, Ross DJ, Strieter RM (2002) Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol 169:1037-1049
3. Binnerts ME, van Kooyk Y, Simmons DL, Figdor CG (1994) Distinct binding of T lymphocytes to ICAM-1, -2 or -3 upon activation of LFA-1. Eur J Immunol 24:2155-2160
4. Biragyn A, Kwak LW (2000) Designer cancer vaccines are still in fashion. Nat Med 6:966-968
5. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW (1999) Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 17:253-258
6. Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH, Broxmeyer HE, Cornetta K (2000) The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 164:4025-4031
7. Brew R, Erikson JS, West DC, Kinsella AR, Slavin J, Christmas SE (2000) Interleukin-8 as an autocrine growth factor for human colon carcinoma cells in vitro. Cytokine 12:78-85
8. Clark-Lewis I, Mattioli I, Gong JH, Loetscher P (2003) Structure-function relationship between the human chemokine receptor CXCR3 and its ligands. J Biol Chem 278:289-295
9. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, Sahagan BG, Neote K (1998) Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J Exp Med 187:2009-2021
10. Crowston JG, Salmon M, Khaw PT, Akbar AN (1997) T-lymphocyte-fibroblast interactions. Biochem Soc Trans 25:529-531
11. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EA (2003) Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 199:221-228
12. Flier J, Boorsma DM, Bruynzeel DP, Van Beek PJ, Stoof TJ, Scheper RJ, Willemze R, Tensen CP (1999) The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. J Invest Dermatol 113:574-578
13. Frederick MJ, Clayman GL (2001) Chemokines in cancer. Expert Rev Mol Med 2001:1-18
14. + T lymphocytes migrating in three-dimensional collagen lattices lack focal adhesions and utilize β1 integrinin-dependent strategies for polarization, interaction with collagen fibers and locomotion. Eur J Immunol 28:2331-2343
15. Fushimi T, Kojima A, Moore MA, Crystal RG (2000) Macrophage inflammatory protein 3alpha transgene attracts dendritic cells to established murine tumors and suppresses tumor growth. J Clin Invest 105:1383-1393
16. Giovarelli M, Cappello P, Forni G, Salcedo T, Moore PA, LeFleur DW, Nardelli B, Carlo ED, Lollini PL, Ruben S, Ullrich S, Garotta G, Musiani P (2000) Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J Immunol 164:3200-3206
17. Gohara R, Nakao M, Ogata Y, Isomoto H, Oizumi K, Itoh K (1997) Histocompatibility leukocyte antigen-A2402-restricted cytotoxic T lymphocytes recognizing adenocarcinoma in tumor-infiltrating lymphocytes of patients with colon cancer. Jpn J Cancer Res 88:198-204
18. Guidoboni M, Gafa R, Viel A, Doglioni C, Russo A, Santini A, Del Tin L, Macri E, Lanza G, Boiocchi M, Dolcetti R (2001) Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol 159:297-304
19. Hauser AE, Debes GF, Arce S, Cassese G, Hamann A, Radbruch A, Manz RA (2002) Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol 169:1277-1282
20. Hellmuth M, Paulukat J, Ninic R, Pfeilschifter J, Muhl H (2004) Nitric oxide differentially regulates pro- and anti-angiogenic markers in DLD-1 colon carcinoma cells. FEBS Lett 563:98-102
21. Hensbergen PJ, Wijnands PG, Schreurs MW, Scheper RJ, Willemze R, Tensen CP (2005) The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J Immunother 28:343-351
22. Homey G, Müller A, Zlotnik A (2002) Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol 2:175-184
23. Jacob L, Somasundaram R, Smith W, Monos D, Basak S, Marincola F, Pereira S, Herlyn D (1997) Cytotoxic T-cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumor cells. Int J Cancer 71:325-332
24. Jacobs N, Moutschen MP, Franzen-Detrooz E, Boniver V, Boniver J, Delvenne P (1998) Organotypic culture of HPV-transformed keratinocytes: a model for testing lymphocyte infiltration of (pre)neoplastic lesions of the uterine cervix. Virchows Arch 432:323-330
25. Jenh CH, Cox MA, Hipkin W, Lu T, Pugliese-Sivo C, Gonsiorek W, Chou CC, Narula SK, Zavodny PJ (2001) Human B cell-attracting chemokine 1 (BCA-1; CXCL13) is an agonist for the human CXCR3 receptor. Cytokine 15:113-121
26. Loetscher M, Gerber B, Loetscher P, Jones SA, Piali L, Clark-Lewis I, Baggiolini M, Moser B (1996) Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med 184:963-969
27. Maaser K, Wolf K, Klein CE, Niggemann B, Zänker KS, Bröker E-B, Friedl P (1999) Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediated MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing matrices. Mol Biol Cell 10:3067-3079
28. Maas-Szabowski N, Stark HJ, Fusenig NE (2000) Keratinocyte growth regulation in defined organotypic cultures through IL-1-induced keratinocyte growth factor expression in resting fibroblasts. J Invest Dermatol 114:1075-1084
29. Mach F, Sauty A, Iarossi AS, Sukhova GK, Neote K, Libby P, Luster AD (1999) Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 104:1041-1050
30. Mitchell MS, Darrah D, Yeung D, Halpern S, Wallace A, Voland J, Jones V, Kan-Mitchell J (2002) Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 20:1075-1086
31. Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, Mayer ME, Knaus WA, Mullins DW (2004) CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res 64:7697-7701 32. Murakami S, Okada H (1997) Lymphocyte-fibroblast interactions. Crit Rev Oral Biol Med 8:40-50
32. Musha H, Ohtani H, Mizoi T, Kinouchi M, Nakayama T, Shiiba K, Miyagawa K, Nagura H, Yoshie O, Sasaki I (2005) Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma. Int J Cancer 116:949-956
33. O'Donovan N, Galvin M, Morgan JG (1999) Physical mapping of the CXC chemokine locus on human chromosome 4. Cytogenet Cell Genet 84:39-42
34. Ohta M, Tanaka F, Yamaguchi H, Sadanaga N, Inoue H, Mori M (2005) The high expression of Fractalkine results in a better prognosis for colorectal cancer patients. Int J Oncol 26:41-47
35. Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR (1998) The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest 101:746-754
36. Rao WH, Hales JM, Camp RDR (2000) Potent costimulation of effector T lymphocytes by human collagen type I. J Immunol 165:4935-4940
37. Rathmell JC, Farkash EA, Gao W, Thompson CB (2001) IL-7 enhances the survival and maintains the size of naive T cells. J Immunol 167:6869-6876
38. Robertson MJ (2002) Role of chemokines in the biology of natural killer cells. J Leukoc Biol 71:173-183
39. Sauty A, Colvin RA, Wagner L, Rochat S, Spertini F, Luster AD (2001) CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11). J Immunol 167:7084-7093
40. Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, Batra RK, Dubinett SM (2000) Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 164:4558-4563
41. Somasundaram R, Jacob L, Swoboda R, Caputo L, Song H, Basak S, Monos D, Peritt D, Marincola F, Cai D, Birebent B, Bloome E, Kim J, Berencsi K, Mastrangelo M, Herlyn D (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62:5267-5272
42. Stanford MM, Issekutz TB (2003) The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo. J Leukoc Biol 74:791-799
43. Starnes HF Jr (1991) Biological effects and possible clinical applications of interleukin 1. Semin Hematol 28:34-41
44. Strieter RM, Belperio JA, Phillips RJ, Keane MP (2004) CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 14:195-200
45. Tasaki A, Yamanaka N, Kubo M, Matsumoto K, Kuroki H, Nakamura K, Nakahara C, Onishi H, Kuga H, Baba E, Tanaka M, Morisaki T, Katano M (2004) Three-dimensional two-layer collagen matrix gel culture model for evaluating complex biological functions of monocyte-derived dendritic cells. J Immunol Methods 287:79-90
46. Tensen CP, Flier J, Van Der Raaij-Helmer EM, Sampat-Sardjoepersad S, Van Der Schors RC, Leurs R, Scheper RJ, Boorsma DM, Willemze R (1999) Human IP-9: a keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). J Invest Dermatol 112:716-722
47. Vicari AP, Caux C (2002) Chemokines in cancer. Cytokine Growth Factor Rev 13:143-154
48. Wei WZ, Miller B, Gutierrez RM (1997) Inhibition of tumor growth by peptide specific cytotoxic T lymphocytes in a three-dimensional collagen matrix. J Immunol Methods 200:47-54
49. Whiting D, Hsieh G, Yun JJ, Banerji A, Yao W, Fishbein MC, Belperio J, Strieter RM, Bonavida B, Ardehali A (2004) Chemokine monokine induced by IFN-gamma/CXC tpdchemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J Immunol 172:7417-7424
50. Yang SK, Eckmann L, Panja A, Kagnoff MF (1997) Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells. Gastroenterology 113:1214-1223
51. Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P, Guerry D, Furth E, Rollins BJ, Putt M, Gimotty P, Swoboda R, Herlyn M, Herlyn D (2005) CXC chemokine ligand 12 (stromal cell-derived factor 1{alpha}) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J Immunol 174:5856-5863
52. Zhang T, Somasundaram R, Berencsi K, Caputo L, Gimotty P, Rani P, Guerry D, Swoboda R, Herlyn D (2006) Migration of cytotoxic T lymphocytes toward melanoma cells in three-dimensional organotypic culture is dependent on CCL2 and CCR4. Eur J Immunol 36:457-467
53. Zibert A, Balzer S, Souquet M, Quang TH, Paris-Scholz C, Roskrow M, Dilloo D (2004) CCL3/MIP-1alpha is a potent immunostimulator when coexpressed with interleukin-2 or granulocyte-macrophage colony-stimulating factor in a leukemia/lymphoma vaccine. Hum Gene Ther 15:21-34